In vitro antisickling activity of cromolyn sodium.
The improvement in sickle cell disease (SCD) children receiving cromolyn sodium therapy prompted us to investigate its antisickling activity in vitro. The number of sickle cells was determined in deoxygenated blood samples from 15 children with severe SCD. At the eight concentrations tested, cromolyn sodium exhibited a significantly higher activity than pentoxifylline, the standard compound. Therefore cromolyn sodium would appear to be an interesting candidate for SCD therapy and deserves further in vivo investigations.
Fall
A B
AB
Laboratoire de Pharmacognosie et Bromatologie, Institut de Pharmacie de l'Université Libre de Bruxelles, Belgium.
Toppet
M
M
Ferster
A
A
Fondu
P
P
Vanhaelen-Fastré
R
R
Vanhaelen
M
M
D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000986:Antisickling Agents / Q000627:therapeutic use; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D006401:Hematologic Agents / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D010431:Pentoxifylline / Q000627:therapeutic use
D000986:Antisickling Agents; D006401:Hematologic Agents; D004205:Cromolyn Sodium; D010431:Pentoxifylline